利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

84 records (took 0.046 seconds)

    Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient
    3.
    发明公开
    Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient 审中-公开

    公开(公告)号：US20240245659A1

    公开(公告)日：2024-07-25

    申请号：US18444342

    申请日：2024-02-16

    Applicant: Corcept Therapeutics Incorporated

    Inventor： Andreas Moraitis

    IPC: A61K31/437 ,  A61K31/4196 ,  A61K45/06 ,  A61P5/38

    CPC classification number: A61K31/437 ,  A61K31/4196 ,  A61K45/06 ,  A61P5/38

    Abstract: Methods and uses are disclosed for treating a subject suffering from a disorder selected from a liver disorder, Cushing's syndrome, or Cushing's Disease, cancer, an infection, an inflammatory condition, a cardiovascular, endocrine, or kidney disease, and combinations thereof, or other disorder for which they may be administered a drug which may cause liver toxicity, without adverse effects on the liver. Such liver disorders include fatty liver diseases are effective for reducing high levels of liver enzymes with a favorable safety profile. The methods and uses comprise administering to the subject an effective amount of a selective nonsteroidal glucocorticoid receptor modulator such as relacorilant, including methods and uses in combination with another drug, without adverse effects on liver enzyme levels, or on liver function. In embodiments, the other drug may be a drug that may cause liver toxicity, such as drugs that inhibit CYP3A enzymes, e.g., itraconazole or ketoconazole.

    TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS USING DAZUCORILANT
    4.
    发明公开
    TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS USING DAZUCORILANT 审中-公开

    公开(公告)号：US20240156806A1

    公开(公告)日：2024-05-16

    申请号：US18496134

    申请日：2023-10-27

    Applicant: Corcept Therapeutics Incorporated

    Inventor： Grace Mann ,  Iulia Cristina Tudor ,  William Guyer ,  Hazel Hunt ,  Joseph Custodio

    IPC: A61K31/4738 ,  A61K31/4152 ,  A61K31/428 ,  A61P25/28

    CPC classification number: A61K31/4738 ,  A61K31/4152 ,  A61K31/428 ,  A61P25/28

    Abstract: Applicant discloses methods and compositions for treating a patient suffering from amyotrophic lateral sclerosis (ALS) comprising administration of a heteroaryl ketone fused azadecalin compound. In embodiments, the heteroaryl ketone fused azadecalin compound is dazucorilant: (R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl) sulfonyl)-4, 4a, 5,6,7,8-hexahydro-1-H-pyrazolo[3,4-g]isoquinolin-4a-yl) (pyridin-2-yl)methanone, having the chemical structure illustrated as




    Suitable doses include daily administration of 150 milligrams and 300 milligrams of dazucorilant. Suitable doses include daily administration of dazucorilant with food, or with water, or with food and water. Daily administration of dazucorilant is effective to increase dazucorilant exposure up to about 2-fold when continued for seven days or more. Administration of such a heteroaryl ketone fused azadecalin compound may comprise oral administration, enteral administration, or other administration. Pharmaceutical compositions comprising dazucorilant are useful in the treatment of patients suffering from ALS. Suitable pharmaceutical compositions comprising dazucorilant include, e.g., pharmaceutical compositions for oral administration and pharmaceutical compositions for enteral administration.

    METHODS FOR REDUCING LIVER FAT and FOR TREATING FATTY LIVER DISORDERS
    5.
    发明公开
    METHODS FOR REDUCING LIVER FAT and FOR TREATING FATTY LIVER DISORDERS 审中-公开

    公开(公告)号：US20240100052A1

    公开(公告)日：2024-03-28

    申请号：US18518289

    申请日：2023-11-22

    Applicant: Corcept Therapeutics Incorporated

    Inventor： Ada Lee ,  Andreas Grauer ,  Joseph Belanoff

    IPC: A61K31/513 ,  A61P1/16

    CPC classification number: A61K31/513 ,  A61P1/16

    Abstract: Applicant discloses methods and compositions for reducing liver fat and for treating fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) including nonalcoholic steatohepatitis (NASH) and nonalcoholic cirrhosis; alcohol related fatty liver diseases including, alcohol fatty liver disease (AFL), alcoholic steatohepatitis (ASH), and alcoholic cirrhosis; and liver fibrosis). Significant liver fat reductions were obtained in human patients after only between 30 to 44 days of administration of 600 mg/day or 900 mg/day of the cyclohexyl pyrimidine glucocorticoid receptor modulator miricorilant. Liver fat reductions ranged from 38.5% to 73.8% (magnetic resonance imaging measurements in 4 of 5 patients receiving miricorilant, measured between 16-64 days after cessation of miricorilant administration). A further effect of miricorilant was an increase in liver alanine amino transferase (ALT) and aspartate amino transferase (AST). Mouse studies showed that miricorilant reduced measures of NAFLD, body weight, liver weight, and liver collagen and galectin-3 levels.

    METHODS OF STIMULATING AN ANTI-TUMOR RESPONSE USING A SELECTIVE GLUCOCORTICOID RECEPTOR MODULATOR
    8.
    发明公开
    METHODS OF STIMULATING AN ANTI-TUMOR RESPONSE USING A SELECTIVE GLUCOCORTICOID RECEPTOR MODULATOR 审中-公开

    公开(公告)号：US20230346774A1

    公开(公告)日：2023-11-02

    申请号：US17793271

    申请日：2021-02-10

    Applicant: Corcept Therapeutics Incorporated

    Inventor： Andrew E. Greenstein ,  Andreas Grauer ,  Stacie Peacock Shepherd

    IPC: A61P35/00 ,  A61K39/395 ,  A61K31/4745 ,  A61K31/337

    CPC classification number: A61K31/4745 ,  A61K31/337 ,  A61K39/3955 ,  A61P35/00 ,  A61K2039/505

    Abstract: Methods of improving immune function in a cancer patient having a solid tumor are disclosed. The improvement in immune function may slow or stop tumor growth, and may reduce tumor load. Methods include administering effective amounts of a cancer treatment and a nonsteroidal glucocorticoid receptor modulator (GRM) or selective GRM (SGRM). The cancer treatment may include administration of a checkpoint inhibitor. GRM or SGRM administration may induce checkpoint-inhibitor sensitivity in the cancer. Improved immune function may include increased CD8+ T-cell activation, increased pro-inflammatory cytokine secretion, increased TNFα secretion, increased IFNy secretion, and other changes as compared to such activation and secretion prior to GRM administration. In embodiments, immune function is improved after 1, 2, 3, or more days of GRM administration. Other patient characteristics may also be improved by the methods disclosed herein. GRMs include heteroaryl-ketone fused azadecalin and octahydro fused azadecalin GRMs. GRM administration includes oral GRM administration.

    Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
    10.
    发明授权
    Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator 有权

    公开(公告)号：US11684612B2

    公开(公告)日：2023-06-27

    申请号：US18084866

    申请日：2022-12-20

    Applicant: Corcept Therapeutics Incorporated

    Inventor： Andreas Moraitis

    IPC: A61K31/437 ,  A61P5/44

    CPC classification number: A61K31/437 ,  A61P5/44

    Abstract: Methods and compositions are disclosed for diagnosing a patient suspected of suffering from, and for treating a patient suffering from, a disorder such as hypercortisolemia, metabolic syndrome, pre-diabetes, diabetes, Cushing's syndrome, Cushing's Disease, hyperglycemia secondary to hypercortisolemia, a liver disease, a cardiac disorder, high blood pressure, a blood clotting disorder, a cancer, a psychological disorder, weight gain, a disorder of glucose control, a bone disorder (e.g., osteoporosis), hypogonadism, pseudoacromegaly, pituitary tumors, functional hypercortisolism, ACTH secreting tumors, peripheral neuropathy, dyslipidemia and other disorders.
    The methods and compositions include administration of a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator (GRM). The preferred heteroaryl-ketone fused azadecalin GRM is relacorilant ((R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone). In some cases, the GRM (e.g., relacorilant) is orally administered. In some cases, the GRM (e.g., relacorilant) is orally administered without food.

Patent Agency Ranking